GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL) » Definitions » Gross-Profit-to-Asset %

PharmaLundensis AB (XSAT:PHAL) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is PharmaLundensis AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. PharmaLundensis AB's annualized Gross Profit for the quarter that ended in Mar. 2024 was kr0.00 Mil. PharmaLundensis AB's average Total Assets over the quarter that ended in Mar. 2024 was kr10.49 Mil. Therefore, PharmaLundensis AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.


PharmaLundensis AB Gross-Profit-to-Asset % Historical Data

The historical data trend for PharmaLundensis AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB Gross-Profit-to-Asset % Chart

PharmaLundensis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 2.01 8.25 - -

PharmaLundensis AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaLundensis AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, PharmaLundensis AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Gross-Profit-to-Asset % falls into.



PharmaLundensis AB Gross-Profit-to-Asset % Calculation

PharmaLundensis AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (8.76+10.963)/ 2 )
=0/9.8615
=0.00 %

PharmaLundensis AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (10.963+10.017)/ 2 )
=0/10.49
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


PharmaLundensis AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB (XSAT:PHAL) Business Description

Traded in Other Exchanges
N/A
Address
Medicon Village, Scheelevagen 2, Lund, SWE, 22381
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL) Headlines

No Headlines